US Pharma MarketingEli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout Eli Lilly gene editing HHS Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT@ASCO Search Log In Try STAT+ My Account Home Newsletter The Readout Five biotech news updates to stay on top of today Eli Lilly spends more…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hi! Hope you had a nice extended weekend.
Today: Eli Lilly’s gene-editing data seems promising for high cholesterol, an AI drug discovery CEO dispelled some AI drug discovery hype, and the new interim FDA chief is so far well received.
Source: STAT News Pharma